<DOC>
	<DOCNO>NCT00626392</DOCNO>
	<brief_summary>The primary purpose study assess effect aspirin ( ASA ) niacin extended-release ( NER ) -induced flushing subject dyslipidemia .</brief_summary>
	<brief_title>Study Evaluate EFFECTS Acetylsalicylic Acid ( ASA ) NiaspanÂ®-Induced Flushing Subjects With Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Subject must 18 year age old . If female , subject either childbearing potential , defined postmenopausal least one year surgically sterile , childbearing potential must agree practice birth control duration study . Have dyslipidemia demonstrate laboratory result . Have glycosylated hemoglobin ( HbA1c ) &gt; /= 9.0 % . Have nephrotic syndrome , dysproteinemias , severe renal failure ( glomerular filtration rate [ GFR ] &lt; 30 mL/minute , calculate creatinine clearance ) . Have unstable angina acute myocardial infarction ( MI ) within three month Screening Visit . Have severe peripheral artery disease evidence intermittent claudication within three month Screening Visit . Have uncontrolled cardiac arrhythmia within three month Screening Visit . Have symptomatic heart failure define dyspnea rest exertion ( mild peripheral edema exclusionary ) . Have systolic blood pressure measurement &gt; 180 mmHg diastolic blood pressure measurement &gt; 110 mmHg Screening Baseline Visit . Have active gout uric acid &gt; /= 11 mg/dL . Have history hepatitis ( acute chronic ) , obstructive liver disease , alanine aminotransferase ( ALT ; serum glutamic pyruvic transaminase [ SGPT ] ) aspartate aminotransferase ( AST ; serum glutamic oxaloacetic transaminase [ SGOT ] ) value &gt; /= 1.3 time upper limit normal ( ULN ) Screening Visit . Have creatine phosphokinase ( CPK ) &gt; /= 3 x ULN Screening Visit . Have use investigational study drug participate investigational study within 30 day Screening Visit . Have health condition laboratory abnormality ( inclusive clinically significant laboratory result Screening Visit ) , , opinion Investigator , may adversely affected procedure study medication study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>